Navigation Links
Stem Cell Innovations' C3A Human Liver Cell Line is Capable of Producing Biosimilar Serum Proteins for Follow-On Biologics
Date:2/24/2009

Blood clotting proteins factor 8 and 9 are first target indications

HOUSTON, Feb. 24 /PRNewswire-FirstCall/ -- Stem Cell Innovations' (Pink Sheets: SCLL) liver assist device program has additional application in the production of biosimilar and novel proteins. "Many of the commercially important therapeutic proteins are liver products and comprise a multibillion dollar market in the US," said James H. Kelly, CEO of SCLL. "Albumin, the clotting factors and alpha-1-antitrypsin are all produced naturally in the liver. Our C3A cell line produces each of these proteins at levels comparable to the natural liver cell. We already have the capability for large scale culture of the C3A cell line and expect that our PluriCell(TM) derived hepatocytes will have similar production capabilities. In addition, the C3A line provides an excellent host for the production of recombinant proteins due to the liver's massive synthetic capability."

In a sign that major pharmaceutical companies are becoming more aggressive about the biosimilar business, Merck is buying Insmed's portfolio of follow-on biologics for $130 million in cash. "We are exploring ways to fund our activities in this area through a spin out or an acquisition," said Kelly.

About Stem Cell Innovations, Inc.

SCLL is a cell biology company based in Houston, TX. The Company's ACTIVTox system is a human liver based model for high throughput toxicity testing. Stem Cell Innovations' proprietary, human pluripotent stem cells, known as PluriCells, have the potential to aid in drug discovery, toxicology, and cell therapy.

Additional information is available at www.stemcellinnovations.com and at www.activtox.com.

ACTIVTox and PluriCells are Trademarks of Stem Cell Innovations, Inc.

Forward-Looking Statement

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The Private Securities Litigation Reform Act of 1995 provides a "safe harbor" for forward-looking statements. Forward-looking statements are not statements of historical facts, but rather reflect our current expectations concerning future events and results. We use words such as "expects," "intends," "believes," "may," "will" and "anticipates" to indicate forward-looking statements. Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements, including, but not limited to, those risks and uncertainties detailed in the Company's periodic reports filed with the Securities and Exchange Commission. We caution that these risk factors may not be exhaustive. We operate in a continually changing business environment, and new risk factors emerge from time to time. We cannot predict these new risk factors, nor can we assess the effect, if any, of the new risk factors on our business or the extent to which any factor or combination of factors may cause actual results to differ from those expressed or implied by these forward-looking statements.

If any one or more of these expectations and assumptions proves incorrect, actual results will likely differ materially from those contemplated by the forward-looking statements. Even if all of the foregoing assumptions and expectations prove correct, actual results may still differ materially from those expressed in the forward-looking statements as a result of factors we may not anticipate or that may be beyond our control. While we cannot assess the future impact that any of these differences could have on our business, financial condition, results of operations and cash flows or the market price of shares of our common stock, the difference could be significant. We do not undertake to update any forward-looking statements made by us, whether as a result of new information, future events or otherwise. You are cautioned.


'/>"/>
SOURCE Stem Cell Innovations, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Inverness Medical Innovations Announces Fourth Quarter 2008 Results
2. Inverness Medical Innovations Schedules Conference Call for 10:00 a.m. ET February 18, 2009 to Discuss Fourth Quarter 2008 Results
3. James Roosevelt, Jr. Joins Inverness Medical Innovations Board of Directors
4. Young Innovations, Inc. Announces Results for 4th Quarter and the Year and Declares Dividend
5. Inverness Medical Innovations to Present at the 2009 UBS Global Healthcare Services Conference on February 10, 2009
6. Young Innovations, Inc. Provides Fourth Quarter Conference Call Details
7. Can payment and other innovations improve the quality and value of health care?
8. Stem Cell Innovations, Inc., Files New Patent Application Regarding Pluripotent Stem Cell Production
9. HC Innovations Expands Management Team, Adding Vice President of Human Resources
10. Pharos Innovations Strengthens Leadership Team, Informatics Program
11. Inverness Medical Innovations Presents the pima(TM) Point-of-Care CD4 Instrument at ICASA 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... , ... Aimed at nurses and employees in the health care world, this ... the nursing and health care industry. It also provides insight to the developing trends ... , As the nursing industry is coming out of one of the biggest recessions ...
(Date:5/26/2016)... ... May 26, 2016 , ... Despite last week’s media ... Janet Yellen and company to wait until March 2017 for an interest rate increase, ... Mack Robinson College of Business. , “The Federal Open Market Committee (FOMC) dot charts ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cabot Corporation, Pfizer, and ... according to court documents and SEC filings. A jury has returned a ... American Optical Corporation, Case No. BC588866, Los Angeles County, California. The jury awarded ...
(Date:5/26/2016)... ... , ... Connor Sports, through its Connor Cares initiative, will continue ... Catchings Legacy Tour that will commemorate the Indiana Fever legend’s hall-of-fame career and ... forms and levels of the game, Connor Sports has committed to a significantly increased ...
(Date:5/26/2016)... ... May 26, 2016 , ... Cardiac arrhythmia is ... impact on long-term patient survival, reports a team of UPMC researchers in the ... in the Journal of Thoracic and Cardiovascular Surgery, provide critical information that will ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... , Deutschland und GERMANTOWN, Maryland ... Zusammenarbeit mit Therawis bedient ... bei Brustkrebs   QIAGEN N.V. (NASDAQ: ... gab heute bekannt, eine Lizenz- und Entwicklungsvereinbarung mit ... Assays für die Onkologie eingegangen zu sein. Ein ...
(Date:5/25/2016)... YORK , May 25, 2016  According to ... reached $381 billion in 2015.  Though these are ... plenty of opportunity for success for companies that ... in search of new growth prospects medical device ... on research and development (R&D) than do companies ...
(Date:5/25/2016)... NORTH CHESTERFIELD, Va. , May 25, 2016 ... commercially-available next-generation sequencing test for wounds and infections. ... fungi, ALL parasites, and select viruses. The test ... infected area. David G. ... advanced molecular testing to facilitate wound healing: "We ...
Breaking Medicine Technology: